BeyondSpring (NASDAQ:BYSI – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Valuation and Earnings
This table compares BeyondSpring and Whitehawk Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeyondSpring | $1.75 million | 13.14 | -$1.01 million | ($0.12) | -4.66 |
| Whitehawk Therapeutics | $7.14 million | 23.08 | -$20.60 million | ($1.12) | -2.58 |
BeyondSpring has higher earnings, but lower revenue than Whitehawk Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BeyondSpring and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeyondSpring | N/A | N/A | -28.88% |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
Institutional and Insider Ownership
40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for BeyondSpring and Whitehawk Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeyondSpring | 1 | 0 | 0 | 0 | 1.00 |
| Whitehawk Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
Whitehawk Therapeutics has a consensus target price of $8.33, indicating a potential upside of 188.35%. Given Whitehawk Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than BeyondSpring.
Risk and Volatility
BeyondSpring has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
Summary
Whitehawk Therapeutics beats BeyondSpring on 8 of the 12 factors compared between the two stocks.
About BeyondSpring
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
